FDA delays decision on blood thinner

June 24, 2008 at 11:37 PM

INDIANAPOLIS, June 24 (UPI) -- Eli Lilly and Co. says the U.S. Food and Drug Administration has extended the review period for the experimental blood thinner prasugrel.

The drug, which would be marketed under the name Effient, will be up for review by the FDA in September, Eli Lilly said Monday. "We remain confident in our prasugrel submission package," said Dr. Jennifer Stotka, vice president for Global Regulatory Affairs at Lilly.

Prasugrel is being co-developed by Daiichi Sankyo Co. in Japan and Indianapolis-based Eli Lilly as a potential treatment for patients with acute coronary syndromes.

Related UPI Stories
Topics: Eli Lilly
Latest Headlines
Trending Stories
New evidence suggests Earth is product of two-planet collision
The physics of pancakes informs glaucoma treatments
New species of fluorescent polyps light up gastropod shells
Expedition finds lost lion population in Ethiopia
Scientists identify butterfly-like insect from the Jurassic age